NSE: CIPLA | BSE: 500087

Strong Performer, Getting Expensive

Download real time

1578.40 9.20 (0.59%)

1.2M NSE+BSE Volume

NSE 03 Sep, 2025 3:31 PM (IST)

127,495.9

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

27 Jan 2022

1578.40

0.59%

Cipla Limited

Cipla Ltd.

SMC online

Cipla Q3 results: Net profit slips marginally to Rs 729 crore, beats estimates For the quarter ending Dec 2021, consolidated Net sales (including other operating income) of Cipla has increased 6% to Rs 5478.86 crore compared to quarter ended Dec 2020. Sales of...

Cipla Ltd. has an average target of 1713.00 from 9 brokers.

Cipla Ltd.

26 Jan 2022

1578.40

0.59%

Cipla (BUY): Growth led by India business

Buy: Cipla Ltd.

BOB Capital Markets Ltd.

Q3 sales growth modest at 6% YoY led by US and India formulations. API sales declined due to slowdown in orders from developed markets

Cipla Ltd. has an average target of 1713.00 from 9 brokers.

Cipla Ltd.

26 Jan 2022

1578.40

0.59%

Cipla

Buy: Cipla Ltd.

Target

ICICI Securities Limited

65 therapeutic categories, with over 50 dosage forms. Cipla supplies branded and generic medicines to over 170 countries globally. Cipla derives 21% of its export revenues from the US followed by 12% from South Africa, 5% from Europe and 16% from RoW markets...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

26 Jan 2022

1578.40

0.59%

Superior execution drives India/US performance

Neutral: Cipla Ltd.

Motilal Oswal

CIPLA delivered a better-than-expected 3QFY22 performance, led by robust growth in the Domestic Formulation (DF) segment, steadily improving sales in North America (NA), and better operating leverage. This was partly offset by a momentary slowdown in API sales in the developed markets. We raise our FY22E/FY23E/FY24E EPS estimate by 3%/6%/4%, factoring in a) market share gains in already launched ANDAs and upcoming potential new launches, such as Lanreotide, b) strong growth in anchor consumer brands in India/South Africa, and c) moderation in the API business outlook. We value...

Cipla Ltd. has an average target of 1713.00 from 9 brokers.

Cipla Ltd.

26 Jan 2022

1578.40

0.59%

CIPLA LTD.

Buy: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

We expect 15% EPS CAGR over FY21-24E from base business (ex Revlimid) given resilient earnings, improving visibility from US and strong free cash flow generation. We broadly maintain our estimates and Buy' rating with TP of Rs1100/share based on 24x Dec 2023E EPS plus Rs20/share for Revlimid....

Cipla Ltd. has an average target of 1713.00 from 9 brokers.

Cipla Ltd.

29 Oct 2021

1578.40

0.59%

CIPLA LTD

Buy: Cipla Ltd.

Geojit BNP Paribas

The company looks to expand its lung leadership globally. Key product launches in US market will maximize value opportunities. Company performance is expected to improve with continued efforts on cost optimization and product improvisation. Hence, we reiterate our BUY rating on the stock with a TP of Rs. 1,050 based on 25x FY23E EPS. Sustained growth momentum in core therapies aids topline...

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

28 Oct 2021

1578.40

0.59%

Cipla Limited

Cipla Ltd.

SMC online

Cipla Q2FY22, PAT rises 7% YoY to Rs 711 crore, beats estimates The drug maker's sales increased 9.56% to Rs 5519.80 crore in Q2 FY22 as compared to Rs 5038.29 reported in Q2 FY21. Its profit before tax increased 7.5% to Rs 995.81 crore in Q2 FY22 as compared to Rs 925.65 reported in Q2 FY21. EBITDA rose 4% year on year to Rs 1,226 crore in Q2 FY22. EBITDA margin for Q2 FY22 stood at 22.2% as compared to 23.4% posted in Q2 FY21. R&D; investments stood at Rs 274 crore in Q2 FY22 with priority projects spends on track....

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

27 Oct 2021

1578.40

0.59%

Efforts on track for big launches in US Generics in FY23

Neutral: Cipla Ltd.

Target

Motilal Oswal

CIPLA delivered an in line result in 2QFY22, led by strong YoY growth in Domestic Formulations (DF) and South Africa. The overall performance was offset by muted showing in the US and API segment....

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

27 Oct 2021

1578.40

0.59%

Cipla

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Indian branded formulations business accounts for ~40% of revenues and enjoys leadership in therapies like respiratory, anti-infective, cardiac, gynaecology & gastro-intestinal Cipla derives 21% of its export revenues from the US followed by 12% from...